ArticleEndocrine2026
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSemaglutide and tirzepatide are widely used for type 2 diabetes and obesity, but comparative post-marketing safety data remain limited.
objectiveTo compare adverse-event reporting patterns for semaglutide and tirzepatide in the FDA Adverse Event Reporting System (FAERS), focusing on gastrointestinal, renal and ocular events, alopecia, serious outcomes, mortality, and reporting chronology.
methodsThis retrospective pharmacovigilance study analyzed FAERS reports submitted from January 2022 through June 2026. After deduplication, 215,337 unique reports remained; predefined exposure criteria identified 60,423 semaglutide-only reports, 143,126 tirzepatide-only reports, and 853 reports listing both drugs without additional suspect active ingredients. Disproportionality was assessed using reporting odds ratios (RORs) with 95% confidence intervals. Multivariable logistic regression, false discovery rate adjustment, and reporting-latency analyses were also performed.
resultsSemaglutide showed higher reporting odds than tirzepatide for impaired gastric emptying (ROR 6.39), intestinal obstruction/ileus (ROR 4.56), acute kidney injury (ROR 2.51), pancreatitis (ROR 2.18), vomiting (ROR 2.11), and optic ischaemic neuropathy (ROR 15.77). Alopecia was relatively more frequently reported with tirzepatide (ROR 0.74). Semaglutide reports had higher adjusted reporting odds of hospitalization (aOR 2.80) and death (aOR 1.21). In an exploratory analysis restricted to male reports, erectile dysfunction was reported in 92 of 16,673 semaglutide reports and 46 of 27,321 tirzepatide reports (ROR 3.29, 95% CI 2.31-4.69; q < 0.001).
conclusionsSemaglutide and tirzepatide exhibited distinct post-marketing reporting patterns. The erectile-dysfunction finding was exploratory and hypothesis-generating. All findings reflect spontaneous reporting rather than comparative clinical risk or causality and require confirmation in population-based studies.
Indexed as
Identifiers
42955519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.